DUBLIN, April 2, 2025 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) introduced right this moment that administration will take part in a webcast panel dialogue “Growth of Orexin Receptor Agonist in Sleep-Wake Issues” on the upcoming 24th Annual Needham Digital Healthcare Convention on Wednesday, April 9, 2025 at 11:45 a.m. EDT (4:45 p.m. BST). The stay webcast could also be accessed underneath the Buyers tab on www.alkermes.com and can be archived for 14 days.
About Alkermes plc
Alkermes plc is a worldwide biopharmaceutical firm that seeks to develop revolutionary medicines within the area of neuroscience. The corporate has a portfolio of proprietary industrial merchandise for the therapy of alcohol dependence, opioid dependence, schizophrenia and bipolar I dysfunction, and a pipeline of scientific and preclinical candidates in improvement for neurological issues, together with narcolepsy and idiopathic hypersomnia. Headquartered in Eire, Alkermes additionally has a company workplace and analysis and improvement heart in Massachusetts and a producing facility in Ohio. For extra data, please go to Alkermes‘ web site at www.alkermes.com.
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
View unique content material to obtain multimedia:https://www.prnewswire.com/news-releases/alkermes-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference-302418938.html
SOURCE Alkermes plc
